TRVI
Live chart
What they do
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine.
For information only · Important disclosures
Grades vs sector
No sector grades for TRVI yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Our models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-06 | -0.11 | -0.11 | -0.9% |
| 2026-05-05 | -0.07 | -0.09 | -23.3% |
| 2026-03-17 | -0.10 | -0.06 | +37.2% |
| 2025-11-13 | -0.10 | -0.08 | +19.1% |
| 2025-08-07 | -0.10 | -0.09 | +11.1% |
| 2025-05-08 | -0.12 | -0.09 | +26.0% |
| 2025-03-18 | -0.12 | -0.11 | +6.1% |
| 2024-11-06 | -0.11 | -0.13 | -15.2% |
Insider trades
$1.6K
$316.2K
$1.6K
$276.5K
Stats refreshed 2026-10-21 18:00:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Important disclosures · Contact desk@coteau.app
Coteau Systematic Strategies publishes stock research and model portfolios. Results are hypothetical unless marked Live. Data: Yahoo Finance (15-min delayed), SEC EDGAR and the House Clerk.
Beta 0.9 · Oct 21, 2026